TFPI2 and hepatocellular carcinoma: For instance, the promoter methylation status of two factors, TFPI2 and IGFBP7, in serum is markedly higher than that in normal subjects and hepatitis patients and may thereby become a non-invasive molecular biomarker for the early diagnosis of HCC in the clinic [37, 38].